Summit gains as positive HARMONi-GI1 data show ivonescimab's OS benefit in biliary tract cancer, exp

Summit Therapeutics, Inc. is upgraded to Buy as negative sentiment bottoms and catalysts approach, d

Summit Therapeutics Inc. (NASDAQ:SMMT) partner Akeso Inc. on Wednesday released positive topline fin

Summit Therapeutics partner Akeso Phase 3 HARMONi-GI1 trial shows ivonescimab outperforms durvalumab

Nasdaq 100 falls 0.6% as traders wait on Nvidia and hot July PCE revives September rate-hike bets. E

U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings

Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) f

Summit Therapeutics Inc. (NASDAQ:SMMT) today noted that its partner Akeso Inc. announced positive to

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso I

Summit Therapeutics Inc. (NASDAQ:SMMT) announced that The Lancet Oncology published primary analysis

Summit Therapeutics reported positive Phase 3 trial results for ivonescimab, extending progression-f

Top analysts upgraded Fluence Energy, Dynatrace, and Advanced Micro Devices, Check out their ratings

Bernstein analyst Jeffrey Walch upgrades Summit Therapeutics (NASDAQ:SMMT) from Underperform to M

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results

First Immunotherapy-Based Regimen to Show Statistically Significant and Clinically Meaningful PFS Be

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of p

Could these 2 stocks outperform most GLP-1-focused companies over the medium term?

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) f

Leerink Partners analyst Daina Graybosch upgrades Summit Therapeutics (NASDAQ:SMMT) from Underper

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026

Summit Therapeutics PLC (NASDAQ: SMMT - Get Free Report) passed above its fifty day moving average d

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtainin

HARMONi-GU1 Is First Global Registrational Clinical Trial of Ivonescimab in a Genitourinary (GU) Can

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the expansion of its

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying auto retailer Carvana Co. (NYSE

"Mad Money" host Jim Cramer recommends buying Carvana and Summit Therapeutics. Reddit "s

Summit Therapeutics PLC (NASDAQ: SMMT - Get Free Report) has earned a consensus rating of "Hold" fro

Summit Therapeutics Inc. is upgraded from Sell to Hold as the FDA reviews its BLA for ivonescimab, w

NEW YORK, July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves

Corporate executives say optimistic things about their companies every day. They appear on earnin

Summit Therapeutics Inc. (NASDAQ:SMMT) on Thursday reported an adjusted loss of 19 cents, better tha

Summit Therapeutics beat second-quarter estimates but warned current cash is insufficient to fund op

Stifel analyst Dara Azar maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the pr

Summit posts a wider Q2 loss with no revenues as ivonescimab advances through late-stage studies, un

Guggenheim analyst Brad Canino maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers

US stock futures higher, Deckers Outdoor shares fall after reporting Q1 results. Other stocks also d

Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript

Liquidity, Capital Resources and Going Concern Going Concern During the three and six months ended J

Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.19) per share which beat the anal

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quar

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) f

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on d

Summit Therapeutics shares updated Phase 3 data, revealing improving overall survival trends for lun

Western Patients Achieved OS HR of 0.76, Consistent with Asian Patients in this Global Phase III Stu

Summit Therapeutics Inc. (NASDAQ:SMMT) today announced it has signed an agreement with Toronto-based

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

As a result of such termination, no securities will be sold pursuant to the proposed underwritten pu

US stock futures lower, Nasdaq down 1%. Super Micro shares down 8.6% after announcing $7B offering t